Lipogen Given FDA GRAS Green Light for Phosphatidylserine

07/09/06 Israel based Lipogen Ltd. has announced that the FDA has approved the GRAS notification of Lipogen PS (phosphatidylserine) patented product line.

Phosphatidylserine is mostly found in brain cells and is involved in numerous functions of neuronal activity. Lipogen PS has been clinically tested in a double-blind, placebo-controlled studies. The research showed significant memory and mental improvements in comparison to the placebo groups.

Lipogen is marketing its PS product, in both powder and liquid versions, worldwide. It can be applied to various key-category applications, such as milk, yogurt products, breakfast cereals, biscuits, meal replacements etc.

“This is the first time that the FDA has approved a PS product as safe for food fortification,” says David Rutenberg, CEO at Lipogen. “Other PS ingredients available on the market are produced with bacterial enzymes while Lipogen PS production complies with non-bacterial enzymatic process. This ‘green-light’ from FDA is a significant move for Lipogen as it aims our non-bacterial PS ingredient into the functional food and beverages marketplace.”
 
Based on the FDA GRAS approval, Rutenberg expresses confidence the company will expand its sales within the food and beverage industry.  “The efficacy of PS has been recognized by the FDA which allows Qualified Health Claims (May 13, 2003).  The GRAS affirmation of Lipogen PS as a functional food ingredient will greatly contribute to the fulfillment of consumer demand for mental functional supplements. Baby boomers are seeking for natural brain solutions that will prevent cognitive dysfunction.”